Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc. (United States) holds 0 active US FDA Type II Drug Master Files and 2 inactive. 17 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Par Pharmaceutical, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/par-pharmaceutical-inc
Overview
Par Pharmaceutical, Inc. is a subsidiary of Endo International plc, specializing in the development, manufacturing, and marketing of generic and specialty pharmaceutical products. The company focuses on delivering high-quality, cost-effective medications to improve patient health.
Therapeutic areas
API / Drug Master Files
Par Pharmaceutical, Inc. holds 0 active (2 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN SPRING VALLEY, NEW YORK.Inactive1985-08-08
- FACILITIES AND CONTROLSInactive1979-02-09
FDA compliance signals
17 FDA enforcement records linked to this company.
- recall — Class II2020-09-02
Failed Impurity /Degradation Specifications
- recall — Class II2020-04-08
Failed Impurities/Degradation Specification: Presence of unknown impurity observed.
- recall — Class III2020-03-25
Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg
- recall — Class III2020-02-19
Labeling: Incorrect or Missing Lot and/or Exp Date: Product incorrectly labeled with an expiration date of August 2022 rather than the correct expiration date of April 2022.
- recall — Class I2019-05-15
Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product
- recall — Class III2018-09-19
Failed impurities/degradation specifications: Finished product contain a known product impurity about current specification levels.
- recall — Class II2016-12-07
Lack of Assurance of Sterility; damage to the internal portion of the dropper tip portion of the container
- recall — Class III2016-11-09
Subpotent Drug; Ethinyl Estradiol
- recall — Class III2016-11-09
Subpotent Drug; Ethinyl Estradiol
- recall — Class III2016-11-09
Subpotent Drug; Ethinyl Estradiol
- recall — Class III2016-11-09
Subpotent Drug; Ethinyl Estradiol
- recall — Class III2016-11-09
Subpotent Drug; Ethinyl Estradiol
- recall — Class III2016-06-22
Failed Impurities/Degradation Specifications: Par Pharmaceutical is recalling Pramipexole Dihydrochloride Extended Release tablets because it contains a known product impurity above currently approved specification levels.
- recall — Class III2015-11-25
Failed Impurities/Degradation Specifications: Out of specification for impurities.
- recall — Class III2015-11-25
Failed Impurities/Degradation Specifications: Out of specification for impurities.
- recall — Class II2015-03-04
Presence of Foreign Substance; oxidized steel, organic material and shredded polypropylene
- recall — Class II2015-01-14
Presence of Foreign Substance: Par Pharmaceutical, Inc. is recalling one lot of HydrALAZINE Hydrochloride tablets due to the presence of small aluminum particles.
Is this Par Pharmaceutical, Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Related companies
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.